Do GLP-1 Medicines Change Cancer Risk? What the Cohort Data Shows About the 13 Obesity-Related Cancers

Picture a man in his fifties whose father had colon cancer. He is starting a low-dose GLP-1 protocol and has read two headlines in the same week. One says these drugs might prevent cancer. The other mentions a thyroid tumor warning printed on the label. He wants to know which one applies to him.

Both headlines come from real studies, and they are less contradictory than they look. This article covers what the largest cohort studies found for the 13 obesity-associated cancers, what changed when researchers looked at people without diabetes, why the thyroid data split, what randomized trials add, and what any of it means for a microdose. The man described here is a composite example, not a real patient.

Do GLP-1 medicines change cancer risk?

GLP-1 medicines have not been shown to raise overall cancer risk, and large observational studies link them with lower rates of several obesity-related cancers. That is the short answer. The longer answer depends on which cancer, which comparison group, and whether the person has diabetes.

The reason anyone expects a link at all is body fat. Researchers group 13 cancers as obesity-associated because excess fat is tied to both a higher chance of developing them and a worse outlook once they appear. The list includes cancers of the colon and rectum, pancreas, liver, gallbladder, kidney, esophagus, stomach, ovary, endometrium, thyroid and postmenopausal breast, along with meningioma and multiple myeloma.

A drug that reduces fat mass and improves insulin levels could plausibly lower some of that risk. A drug that stimulates a receptor found in thyroid tissue could plausibly raise a different risk. Both hypotheses have been tested in the same kinds of datasets, which is why the results need to be read cancer by cancer rather than as one verdict.

What did the 1.6 million patient study find?

The largest study found that GLP-1 users with type 2 diabetes had lower risk than insulin users for 10 of 13 obesity-associated cancers. Wang and colleagues published the analysis in JAMA Network Open in 2024. They drew 1,651,452 adults with type 2 diabetes from a database of 113 million US health records and followed them for up to 15 years.

The biggest gaps were in gallbladder cancer, with a hazard ratio of 0.35, meningioma at 0.37, pancreatic cancer at 0.41 and liver cancer at 0.47. Colorectal cancer came in at 0.54. Endometrial and kidney cancer showed smaller reductions, at 0.74 and 0.76. GLP-1 drugs were not associated with lower risk of postmenopausal breast cancer or thyroid cancer.

Insulin is a tough comparison, though. People who need insulin often have longer-standing or harder-to-control diabetes, and insulin itself tends to cause weight gain. Matching on recorded characteristics helps, but it cannot account for everything a prescriber knew when choosing a drug.

Why does the comparison drug change the answer?

The comparison drug changes the answer because each cohort study measures GLP-1 users against a specific alternative, not against nothing. In the same JAMA Network Open study, GLP-1 drugs showed no lower risk for any cancer when compared with metformin. Kidney cancer risk was actually higher in GLP-1 users than metformin users, with a hazard ratio of 1.54.

Metformin users tend to have earlier, milder diabetes, and metformin has its own long-running research interest as a possible cancer modifier. The kidney finding is a single association in a single dataset, and the authors described their results as preliminary. It is still worth knowing about, because it shows how easily a headline can flip depending on which bar is shown.

What about people with obesity but no diabetes?

People with obesity and no diabetes also showed lower rates of obesity-associated cancers on GLP-1 drugs, in two 2026 studies. Hsu and colleagues at Houston Methodist published the first in Annals of Oncology. From 229,467 eligible adults, they matched 80,899 GLP-1 users to 80,899 people who had received diet or exercise counseling. Mean age was 47.2 years.

Over a median follow-up of 2 years, GLP-1 users had a hazard ratio of 0.59 for any of the 13 obesity-associated cancers. The lower rate held across sex, BMI and drug subgroups, with one exception: it was not seen in Black patients. A second 2026 study in the Journal of Gastrointestinal Surgery compared 662,013 semaglutide or tirzepatide users with 272,343 bariatric surgery patients and 158,446 users of older weight-loss drugs.

Beating bariatric surgery on colorectal and pancreatic cancer is a surprising result, since surgery usually produces more weight loss than drugs. Two years of follow-up is also short for cancers that take many years to develop. A drop that appears this quickly may partly reflect differences in screening, health-care contact or who gets prescribed a GLP-1 in the first place. The Annals of Oncology authors stated that prospective trials are needed to confirm causality.

Do GLP-1 drugs raise thyroid cancer risk?

Whether GLP-1 drugs raise thyroid cancer risk is unsettled, because two well-run national studies disagree. Pasternak and colleagues analyzed nationwide registers in Denmark, Norway and Sweden for a 2024 BMJ study. Thyroid cancer developed in 76 of 145,410 GLP-1 users and 184 of 291,667 users of DPP-4 inhibitors, a different class of diabetes drug.

The Scandinavian hazard ratio was 0.93, and the upper limit of its confidence interval ruled out more than a 31% increase in relative risk. For medullary thyroid cancer, the rare type named in the label warning, the hazard ratio was 1.19 with a very wide interval, because there were so few cases.

A 2023 French study in Diabetes Care by Bezin and colleagues pointed the other way. Comparing 2,562 people with thyroid cancer against 45,184 matched controls, it found that 1 to 3 years of GLP-1 use was linked to higher risk of all thyroid cancer, with a hazard ratio of 1.58, and of medullary thyroid cancer, at 1.78.

One explanation often raised is detection: people starting a new drug see doctors more often, and more neck imaging finds more small thyroid cancers. That has not been proven either way. Our article on the thyroid question and the GLP-1 warning covers who is excluded from treatment and why routine calcitonin testing is not recommended.

What do randomized trials show about cancer?

Randomized trials show no increase in overall cancer risk with semaglutide or tirzepatide, but they are too short and too small to settle rare cancers. A 2025 meta-analysis in Endocrinology and Metabolism by Kamrul-Hasan and colleagues pooled 13 tirzepatide trials with 13,761 participants lasting 26 to 72 weeks. The risk ratio for any cancer was 0.78, which was not statistically different from the control groups.

A 2023 semaglutide meta-analysis by Nagendra and colleagues combined 37 randomized trials and 19 real-world studies. Compared with placebo, the odds ratio was 0.95 for all neoplasms, 0.25 for pancreatic cancer and 2.04 for thyroid cancer, and none of those differences was significant. The authors concluded that semaglutide was not associated with increased cancer risk. Trial data are the strongest protection against bias, but a year or so of follow-up cannot answer questions about cancers that develop over a decade.

Why would a GLP-1 drug affect cancer at all?

A GLP-1 drug could affect cancer mainly through what it does to body weight and metabolism, although this has not been proven in people. Excess fat raises insulin levels, inflammatory signals and, after menopause, estrogen made in fat tissue. Each of those is thought to feed tumor growth in at least some of the 13 obesity-associated cancers.

Some of the largest associations in the Wang study were for organs that GLP-1 drugs and weight loss reach directly, such as the liver, pancreas and gallbladder. Fatty liver disease is a known path to liver cancer, which is one reason the liver result draws attention. Our guide to GLP-1 microdosing and fatty liver goes deeper on that link.

The pancreatic result is worth a note of its own. For years the concern ran the other way, with questions about whether GLP-1 drugs might raise pancreatic risk. The large cohorts and trial meta-analyses described here did not find that. Our article on pancreas health and lipase covers the pancreatitis side of the story.

What does this mean for GLP-1 microdosing?

For GLP-1 microdosing, the cancer research says nothing direct, because microdoses were never measured. Every study described here used standard doses in trials or in routine prescribing, and none reported results for people on deliberately low doses. Any cancer association, good or bad, has simply not been measured at microdose levels.

One detail in the 2026 Journal of Gastrointestinal Surgery study is directly relevant. Therapeutic-dose GLP-1 use was linked to lower colorectal and pancreatic cancer rates, but use at any dose showed no significant differences. If the cancer associations are real, they may depend on the fuller doses and larger weight loss that microdosing does not aim for. Selling a microdose as cancer prevention would go well beyond the evidence.

What does carry over is ordinary cancer prevention. Age-appropriate screening, especially colorectal screening for anyone with a family history, matters far more than any drug association in this article. The thyroid exclusions also apply at every dose. The Wegovy prescribing label lists a personal or family history of medullary thyroid cancer, or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), as a contraindication. For the man with a family history of colon cancer, the useful step is to make sure his colonoscopy is up to date, not to count on the protocol.

What is the takeaway?

The takeaway is that GLP-1 medicines have a reassuring cancer record so far, with lower rates of several obesity-related cancers in very large observational studies and no overall increase in randomized trials. The thyroid question remains open, the kidney finding against metformin needs follow-up, and no trial has tested cancer prevention. Microdosing sits outside all of this data, so it should be judged on its own goals rather than on cancer claims borrowed from full-dose studies.

Frequently asked questions

Clinical references

1. Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.21305
2. Hsu AH, Ramirez PT, Chang YH, et al. GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults. Annals of Oncology. 2026. doi:10.1016/j.annonc.2026.04.013
3. Cancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs. Journal of Gastrointestinal Surgery. 2026. doi:10.1016/j.gassur.2026.102497
4. Pasternak B, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024. doi:10.1136/bmj-2023-078225
5. Bezin J, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023. doi:10.2337/dc22-1148
6. Kamrul-Hasan ABM, Alam MS, Dutta D, et al. Tirzepatide and cancer risk in individuals with and without diabetes: a systematic review and meta-analysis. Endocrinology and Metabolism. 2025. doi:10.3803/EnM.2024.2164
7. Nagendra L, Bg H, Sharma M, Dutta D. Semaglutide and cancer: a systematic review and meta-analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2023. doi:10.1016/j.dsx.2023.102834
8. WEGOVY (semaglutide) injection, prescribing information. DailyMed, National Library of Medicine. Accessed October 9, 2026. dailymed.nlm.nih.gov